Epithelial-to-mesenchymal transition (EMT) is another critical step in metastatic progression, and HNK treatment effectively inhibits EMT in breast cancer cells by abrogating activation of STAT3 which leads to inhibition of ZEB1 and upregulation of cadherin 120. The gene discussed is STAT3; the disease is breast carcinoma.